Azelastine – the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of SARS-CoV-2
CEBINA GmbH, Central European Biotech Incubator and Accelerator with its partner URSAPHARM Arzneimittel GmbH, today announce new results demonstrating that azelastine, the active drug in Pollival®, URSAPHARM’s widely available anti-allergy nasal spray, is an effective anti-viral against the globally dominant omicron SARS-CoV-2 variant in laboratory conditions. Previously, CEBINA and URSAPHARM have demonstrated that azelastine […]
Continue Reading